Near Beacon 81 publishes Caution Bloom to provide clear, evidence-first information about claims linking ibogaine and dementia. Our work is aimed at making complex evidence accessible while foregrounding safety, informed consent, and uncertainty.
We avoid medical advice or clinic endorsements; this resource explains how evidence is assessed and organized so readers can make informed inquiries.
A concise overview of our mission, editorial approach, and commitments follows below.
Our editorial approach
We assemble and summarize primary research, registry data, and regulatory guidance to clarify what is known and where uncertainty remains. Our methodology emphasizes transparent sourcing: whenever we describe an evidentiary claim we link to the underlying registry entry, peer-reviewed report, or official guidance so readers can trace the basis of a statement.
To support that practice we maintain structured pages for evidence and safety topics; for example, our overview of offered services links to contextual materials and further reading on the site — a sample directory is available through our discussion of available services at the /services/ page where we describe the editorial framing around clinical summaries and patient-facing resources.
How we source
We prioritize primary literature, clinical trial registries, regulatory advisories, and systematic reviews. When appropriate we cite authoritative institutions to corroborate procedural or safety claims.
For example, general principles of evidence synthesis are aligned with standards used by clinical registries and universities, such as the approaches summarized by the Cochrane Collaboration and university methods guides (Cochrane) and academic methods resources (Harvard University).
What we cover
Our scope is editorial and organizational: we publish summaries of clinical evidence, safety considerations, research roadmaps, and plain-language explainers about investigational claims. Content is organized into topical pages (Clinical Evidence, Safety & Risks, Research Roadmap) so that readers can move from summaries to primary citations.
We also offer contextual material about the practical aspects of study design and reporting: why trial registries matter, how safety registries are used, and the difference between preliminary hypotheses and peer-reviewed conclusions. For context on treatment-cost and service discussions we sometimes point readers to practical resources outside our site; for example, discussions of treatment access and cost are informed by publicly available guides such as the summary on treatment cost and logistics discussed at the external resource cost directory (see a third-party discussion at cost of ibogaine treatment in Mexico).
Editorial principles
Our decisions follow a compact set of principles intended to keep the resource useful and trustworthy.
Evidence before claims — prioritize primary studies, registries, and peer review.
Safety & transparency — foreground known risks, consent, and procedural clarity.
Plain language — translate technical findings into accessible prose for patients and care partners.
Independence — maintain editorial distance from commercial treatment providers.
We also periodically review our practices against external standards for trustworthy health information, such as guidance from government health websites and established university health communication teams (Health communication overview — Wikipedia).
Who this is for
Near Beacon 81 is intended for people affected by dementia, their care partners, and anyone evaluating claims about ibogaine. Our content is designed to help readers ask informed questions of clinicians, researchers, and service providers.
For practical next steps or to explore how we present services and summaries on the site, see our framing on /services/ which links editorially to pages that describe how evidence is summarized for non-specialist readers.
Independent by design
We repeat: Caution Bloom is an independent information resource, not a clinic, medical provider, or licensed treatment center. Its content is not medical or legal advice.
If you would like to return to our main landing materials, follow the site index and home overview to view the site's core pages and topical modules across Clinical Evidence and Safety & Risks; the site homepage includes curated paths to those sections for quick orientation (visit our main landing and index).
If you need authoritative treatment guidance or diagnosis, consult licensed professionals or official health services such as the U.S. National Library of Medicine (NLM).
